On Thursday, Praxis Precision Meds earned an upgrade to its Relative Strength (RS) Rating, from 68 to 72.
Can You Really Time The Stock Market?
IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the best-performing stocks typically have an RS Rating of at least 80 as they begin their biggest climbs. See if Praxis Precision Meds can continue to show renewed price strength and clear that threshold.
While the stock is not near an ideal buy point right now, see if it manages to form and break out of a proper base.
The company posted 0% EPS growth in its most recent report. Sales gains came in at -100%. Keep an eye out for the company's next round of numbers on or around Aug. 4.
The company holds the No. 199 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte, TG Therapeutics and Gilead Sciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
